Form 8-K - Current report:
SEC Accession No. 0001651308-22-000029
Filing Date
2022-02-25
Accepted
2022-02-25 07:03:44
Documents
14
Period of Report
2022-02-25
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bgne-20220225.htm   iXBRL 8-K 42221
2 EX-99.1 exhibit991-q42021earningsr.htm EX-99.1 150442
6 bgnenewlogo2a.jpg GRAPHIC 16225
  Complete submission text file 0001651308-22-000029.txt   378459

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bgne-20220225.xsd EX-101.SCH 1990
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bgne-20220225_lab.xml EX-101.LAB 25166
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bgne-20220225_pre.xml EX-101.PRE 13201
8 EXTRACTED XBRL INSTANCE DOCUMENT bgne-20220225_htm.xml XML 11521
Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filer) CIK: 0001651308 (see all company filings)

EIN.: 981209416 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37686 | Film No.: 22674373
SIC: 2834 Pharmaceutical Preparations